









Markets
/
Stocks
/
nasdaq-ams
/

American Shared Hospital Services

AMS

2.530USD

+0.040+1.61%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

16.39MMarket Cap

LossP/E TTM



American Shared Hospital Services

2.530

+0.040+1.61%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a . Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

113 / 167

Overall Ranking

408 / 4720

Industry

Professional & Commercial Services

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

4.500

Target Price

+80.72%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

American Shared Hospital Services is a provider of turn-key technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services. Its segments include Leasing, and Retail. The Leasing segment comprises the Company’s medical equipment leasing. The Retail segment comprises facilities in Peru and Ecuador. Its products include MR Guided Radiation Therapy Linacs, Advanced Digital Linear Accelerators, Proton Beam Radiation Therapy Systems (PBRT), Brachytherapy systems and suites, and through the Company’s subsidiary, GK Financing LLC., the Leksell Gamma Knife product and services. PBRT is an alternative to traditional external beam, photon-based radiation delivered by linear accelerators. The Gamma Knife treats selected malignant and benign brain tumors, arteriovenous malformations, and functional disorders including trigeminal neuralgia (facial pain). It also provides the equipment and planning, installation, reimbursement and marketing support services.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 43.52% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 28.34M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 64.61.

Undervalued

The company’s latest PE is -6.72, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 4.21M shares, increasing 2.85% quarter-over-quarter.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 6.91, which is lower than the Professional & Commercial Services industry's average of 7.40. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 7.07M, representing a year-over-year increase of 0.21%, while its net profit experienced a year-over-year increase of 107.77%.

Score

Industry at a Glance

Previous score

6.91

Change



Financials

7.14

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.70

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

6.47

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.11

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.12

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 1.20, which is lower than the Professional & Commercial Services industry's average of 2.38. Its current P/E ratio is -6.61, which is -491.66% below the recent high of 25.90 and 238.87% above the recent low of 9.18.

Score

Industry at a Glance

Previous score

1.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 113/167

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

There is no earnings forecast score for this company; the Professional & Commercial Services industry's average is 7.62. The average price target for American Shared Hospital Services is 4.50, with a high of 4.50 and a low of 4.50.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 6.48, which is lower than the Professional & Commercial Services industry's average of 7.29. Sideways: Currently, the stock price is trading between the resistance level at 2.59 and the support level at 2.39, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.48

Change

0.28

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.010

Neutral

RSI(14)

55.161

Neutral

STOCH(KDJ)(9,3,3)

53.834

Buy

ATR(14)

0.088

High Vlolatility

CCI(14)

48.440

Neutral

Williams %R

30.000

Buy

TRIX(12,20)

-0.104

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

2.449

Buy

MA10

2.453

Buy

MA20

2.467

Buy

MA50

2.508

Buy

MA100

2.511

Buy

MA200

2.741

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Stachowiak (Raymond C)

1.51M

+7.84%

Bates (Ernest A)

592.21K

Zucker (Anita G.)

586.47K

+15.42%

Ruffle (John F)

410.48K

Dimensional Fund Advisors, L.P.

209.96K

The Vanguard Group, Inc.

Star Investors

181.24K

Corient Private Wealth LLC

160.56K

Delanois (Gary)

120.00K

Bridgeway Capital Management, LLC

96.69K

-63.26%

Renaissance Technologies LLC

Star Investors

69.90K

-1.86%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 2.91, which is lower than the Professional & Commercial Services industry's average of 4.25. The company's beta value is 0.25. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.